UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
18.59
+0.11 (0.60%)
Mar 19, 2026, 4:00 PM EDT - Market closed

UroGen Pharma Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
112.1173.0695.8256.2245.59
Short-Term Investments
9.7164.741.9744.5644.78
Cash & Short-Term Investments
121.81237.76137.79100.7890.37
Cash Growth
-48.77%72.55%36.73%11.52%-12.47%
Accounts Receivable
33.0820.315.4412.711.72
Inventory
16.469.235.674.334.83
Other Current Assets
14.678.8510.2811.17.48
Total Current Assets
186.02276.14169.19128.91114.39
Net Property, Plant & Equipment
9.093.792.363.753.15
Long-Term Investments
-5.024.5-0.68
Other Long-Term Assets
5.340.772.262.961.53
Total Assets
200.46285.71178.31135.62119.75
Accounts Payable
27.7227.4316.5412.3812.1
Accrued Expenses
13.5210.5710.818.266.95
Other Current Liabilities
5.197.953.863.283.33
Total Current Liabilities
46.4245.9531.2123.9222.38
Long-Term Debt
122.21121.7398.5597.54-
Long-Term Leases
6.121.650.841.590.4
Other Long-Term Liabilities
131.18125.18112.92101.9488.56
Total Long-Term Liabilities
259.51248.57212.31201.0688.95
Total Liabilities
305.93294.51243.52224.98111.33
Common Stock
0.130.120.090.060.06
Additional Paid-in Capital
854.09797.25614.04487.79475.7
Accumulated Other Comprehensive Income
0.020.060.01-0.11-0.03
Retained Earnings
-959.72-806.22-679.35-577.1-467.32
Shareholders' Equity
-105.47-8.8-65.21-89.368.41
Total Liabilities & Equity
200.46285.71178.31135.62119.75
Total Debt
128.33123.3999.499.120.4
Net Cash (Debt)
-6.53114.3738.391.6589.97
Net Cash Growth
-197.90%2221.28%-98.16%-11.58%
Net Cash Per Share
-0.142.671.330.074.03
Book Value
-105.47-8.8-65.21-89.368.41
Book Value Per Share
-2.19-0.21-2.26-3.920.38
Tangible Book Value
-105.47-8.8-65.21-89.368.41
Tangible Book Value Per Share
-2.19-0.21-2.26-3.920.38
Updated Mar 2, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q